NCT01542242

Liraglutide Use in Prader-Willi Syndrome

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Vancouver General Hospital · Academic / Other
• Sex: Male
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

Liraglutide is a glucagon like peptide -1 (GLP-1) agonist, which is approved for use in patients with type 2 diabetes. Studies of liraglutide have shown an appetite suppressive effect and has been associated with weight loss in patients with type 2 diabetes. Liraglutide use in the treatment of PWS is limited to one case report by Cyganek et el (See attached Citation). In this case report, the subject showed improvements in hemoglobin A1c and body weight over 14 weeks. The investigators plan to examine the use of liraglutide in a single subject with Prader Willi Syndrome and type 2 diabetes for one year. The investigators will examine clinical parameters, clinical assessment of hunger, and biochemical markers of diabetes and lipid control.

Conditions

• Diabetes Mellitus Type 2
• Prader Willi Syndrome

Interventions

Type	Name	Description
DRUG	Liraglutide	Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.

Timeline

• Start date: 2012-02-01
• Primary completion: 2013-03-01
• Completion: 2013-03-01
• First posted: 2012-03-02
• Last updated: 2015-12-09

Locations

1 site across 1 country: Canada